Growth Prospects Remain Intact

Despite a mixed performance in the financial year (FY) 2019, on the back of rising raw material prices and subdued business segment performance, analysts remain positive on the growth prospects of Alkem Laboratories. This leading pharmaceutical company has been ranked, the number one anti-infective company for over 10 years. It was the sixth largest pharmaceutical company in India in terms of domestic sales for the fiscal year 2018. The company markets its high-quality branded generics, generic drugs, active pharmaceutical ingredients (APIs) in India and over 50 countries. Today, it holds a comprehensive portfolio of over 750 brands, covering all major therapeutic segments coupled with a robust pan India sales and distribution network. Alkem’s management indicated that beginning of FY19, it streamlined the company’s distribution process, which led to the shifting of some of...